Research
KPV: what the evidence shows
KPV is sold as the working end of an anti-inflammatory hormone. The laboratory work FDA reviewed says it does not bind the receptors that hormone acts through. Nobody has published a study giving it to a person, and the products on sale are injectables and capsules while regulators were shown a topical cream.
- The KPV board ranks no provider, and carries the dated regulatory position that explains why.
- Set against another compound on the same evidence standard: BPC-157 vs KPV.
What KPV is
KPV is three amino acids: lysine, proline and valine. It is the tail end of alpha-melanocyte-stimulating hormone, a hormone made in the pituitary gland that the body already produces.
Alpha-MSH does two well-described things. It drives melanin production, which is the pigment effect, and it damps inflammation. Those two jobs run through different receptors, and the anti-inflammatory one runs through the melanocortin receptors labeled MC3, MC4 and MC5.
The sales logic follows naturally. Take the anti-inflammatory hormone, keep the short active piece, skip the pigment effect. It is a tidy story and the receptor data does not support it.
The mechanism claim, checked against the binding studies
FDA's reviewers went through the receptor literature and reached a conclusion in one sentence. Several lines of evidence suggest that melanocortin receptors are unlikely to be the molecular targets underlying the anti-inflammatory and wound-healing properties of KPV.
Three findings sit behind that. In laboratory studies KPV could not displace radiolabelled alpha-MSH from rat brain tissue, from mouse melanoma cells, or from macrophages engineered to express the MC1 receptor. Unlike alpha-MSH, KPV did not raise cyclic AMP in those macrophages. Studies using both drug and genetic approaches failed to show that the MC2, MC3 and MC4 receptors were involved in the anti-inflammatory and wound-healing effects reported for KPV.
Researchers have proposed other routes instead, including suppression of a transcription factor called nuclear factor kappa-B and transport through an intestinal peptide transporter. Those are hypotheses under investigation, not established mechanisms.
Nothing here says KPV does nothing. It says the reason it is supposed to work is not the reason given on the label.
The human record is empty, and a regulator said so directly
Absence claims deserve suspicion, so here are three independent checks that agree.
A PubMed search in September 2026 for KPV alongside peptide terms returns 47 records, none of them tagged as a randomized controlled trial and none tagged as a clinical trial of any kind. Through the same two filters in the same session, aspirin returns 5,085 and 7,015 respectively, and a nonsense search term returns zero.
ClinicalTrials.gov returns no registered study naming KPV as an intervention. Through the identical query in the same session, aspirin returns 2,181 studies and semaglutide 748.
FDA said it plainly in its own review. Published literature did not reveal studies in which compounded products containing KPV were used in humans, and the agency did not find any information on these substances administered in humans. Its separate safety page states that FDA has not identified any human exposure data on KPV drug products by any route.
One caveat belongs with those numbers. Twenty-seven of the 47 records carry the index tag for humans, which marks a paper as involving human subjects or human tissue. Cell lines derived from people carry that tag. It is not evidence that anyone was given KPV.
What was reviewed and what is actually on sale
KPV was evaluated for wound healing and inflammatory conditions when it came before the FDA Pharmacy Compounding Advisory Committee in July 2026. The product form put forward was a 0.1 percent topical cream and gel.
The market looks nothing like that. FDA's own survey found KPV promoted in oral, injectable, topical and nasal spray formulations, for inflammatory conditions, wound healing, skin health and protection against nerve damage and stroke.
A topical cream and a subcutaneous injection are different products with different risks, and only one of them was assessed. Injection is where the immunogenicity concern lives, and it is the form the review did not cover.
The paperwork problem
The nomination did not include a certificate of analysis for the free base form at all. For the salt form, the certificate covered purity and nothing else.
FDA noted what was missing: impurity limits and testing results, aggregate testing, and microbiological measures. Without those, the agency stated it could not evaluate identity, purity or impurity profile.
The nominator also could not be pinned to one substance. It was unclear from the package whether the nomination was for the free base or the acetate salt, which are different active ingredients. The nomination was later withdrawn, and FDA evaluated both forms on its own initiative.
What FDA concluded
The agency proposed not adding either form of KPV to the list of substances that may be used in compounding under section 503A.
Its summary named four things. The substances are not well characterized chemically. The extent of use in compounding is unknown. There is no information on their use in humans to support a conclusion about safety or effectiveness. Approved therapies already exist for wound management and for inflammatory diseases including psoriasis and eczema.
The grade on this site is the lowest of three tiers, no controlled human evidence, and it means exactly what it says. Nothing about this record shows KPV is harmful. It shows that the questions a buyer would want answered have not been asked.
How to read a KPV product page
Two checks catch most of what goes wrong. First, look at what the citations studied. Papers about alpha-MSH are not papers about KPV, and papers in mice or in cultured cells are not papers in people.
Second, look at whether the form being sold matches the form the research used. A cream study does not support an injection, and neither supports a capsule.
The KPV board on this site carries the current regulatory position with the date it was checked.
Key takeaways
- KPV is a three-amino-acid tail fragment of alpha-melanocyte-stimulating hormone.
- FDA concluded melanocortin receptors are unlikely to be the molecular targets behind its reported effects.
- No published study administers KPV to humans, and FDA said so directly in July 2026.
- A September 2026 search returned 47 records, zero controlled trials and zero registered studies.
- Regulators evaluated a 0.1 percent topical cream; the market sells injectables, capsules and nasal sprays.
- The nomination carried no certificate of analysis for the free base form and did not identify which form it meant.
Frequently asked questions
Has KPV ever been given to a person in a study?
No published study reports it. FDA stated in July 2026 that it found no information on KPV administered in humans, and that published literature revealed no studies in which compounded KPV products were used in humans. A September 2026 search returns no randomized controlled trial and no registered study on ClinicalTrials.gov, with aspirin returning thousands through the identical filters in the same session.
Is KPV the active part of alpha-MSH?
That is the marketing claim, and the receptor evidence FDA reviewed argues against it. KPV could not displace alpha-MSH from its binding sites in three different laboratory preparations, and it did not produce the cellular signal alpha-MSH produces. FDA concluded that melanocortin receptors are unlikely to be the molecular targets behind KPV's reported effects. Other mechanisms have been proposed and none is established.
Is injectable KPV the version regulators looked at?
No. The products put forward were a 0.1 percent topical cream and gel. Injectable, oral and nasal KPV products are sold, and FDA's survey of the market found all of them, but the evaluation covered the topical form. Injection is the route where the immunogenicity concern applies most directly, and it was not the route assessed.
Why does the KPV board have no providers on it?
Because a compounded KPV product cannot lawfully be dispensed today, so a scored board would have nothing honest to rank. The board explains the position and carries the date it was last checked rather than presenting an empty table as a shortage of sellers.
Is KPV dangerous?
Nothing in the record establishes that, and nothing in it establishes the opposite. FDA's position is that it lacks the information needed to know whether KPV would cause harm if given to humans, which is a statement about missing data rather than about the molecule. The specific structural concern it raised is that peptides given by injection can provoke an immune response, and impurity and aggregate data that would let anyone judge that risk was not available.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- FDA Briefing Document for KPV-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee — U.S. Food and Drug Administration, May 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration, April 2026
- Meeting of the Pharmacy Compounding Advisory Committee — agenda and uses evaluated — U.S. Food and Drug Administration, July 2026
- PubMed literature census for KPV, run with a positive control through the same filters — National Library of Medicine, September 2026
- Registered study census for KPV, run with a positive control through the same query — ClinicalTrials.gov, National Library of Medicine, September 2026